Environmental Modification Convention

OrangeGrid Announces Timios Partnership

Retrieved on: 
Thursday, June 2, 2022
LLC, CEO, SVP, Partnership, Ecosystem, Multimedia, BPO, Environmental Modification Convention, Solution, Industry, Learning, SAP Solution Manager, Financial technology, Real estate, Online shopping

DALLAS, June 2, 2022 /PRNewswire/ -- OrangeGrid, LLC ("OrangeGrid"), and Timios, Inc. ("Timios") announced a strategic partnership making Timios the preferred provider of title, escrow, valuation and asset management services within OrangeGrid's GridReady default management ecosystem.

Key Points: 
  • DALLAS, June 2, 2022 /PRNewswire/ -- OrangeGrid, LLC ("OrangeGrid"), and Timios, Inc. ("Timios") announced a strategic partnership making Timios the preferred provider of title, escrow, valuation and asset management services within OrangeGrid's GridReady default management ecosystem.
  • Additionally, Timios has made a significant equity investment in OrangeGrid to increase distribution capacity, and the companies will collaborate on a number of co-marketing initiatives to accelerate market adoption of the solution.
  • Timios is excited to join OrangeGrid at the forefront of the digitization of mortgage servicing, enabling our servicing clients to experience the power of process integration that only OrangeGrid can provide," said Ray Davison, CEO of Timios.
  • Mortgage servicers interested in learning more about the GridReady ecosystem and the Timios title and escrow services within GridSource should contact Dominic Baglio, SVP of Solutions Management at OrangeGrid ( [email protected] ) or Matt Golden, President of Timios ( [email protected] ).

Nonprofit Alliance of Consumer Advocates helped a Homeowner get caught up on her mortgage and get a lower interest rate

Retrieved on: 
Wednesday, June 1, 2022
U.S. federal government response to the COVID-19 pandemic, Consumer, Modification, FREE, David Horowitz (consumer advocate), Loan modification in the United States, Creditor, Environmental Modification Convention, State, ZERO, Affordable housing, Federal law, Family, Trustee Sales Guarantee, COVID19, Real estate, Insurance

COSTA MESA, Calif., June 1, 2022 /PRNewswire-PRWeb/ -- If someone is in a position where they cannot make their regular mortgage payments, a Loan Modification is a great way to save their right to homeownership and improve their financial situation. While forbearance may be a short-term solution, a loan modification will permanently modify their existing terms. For example, a lower interest rate, extended repayment period, and lower monthly payments may be the perfect solution for their financial situation.

Key Points: 
  • For example, a lower interest rate, extended repayment period, and lower monthly payments may be the perfect solution for their financial situation.
  • The goal of a Loan Modification is to lower the amount of money a homeowner owes to their Lender while preventing Foreclosure.
  • Ms. Joanne Gallon is grateful to work with the Nonprofit Alliance of Consumer Advocates.
  • Mr. De La Vega, Nonprofit Alliance of Consumer Advocates, 1 8556222435, [email protected]

Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Retrieved on: 
Thursday, April 28, 2022
HIV disease progression rates, CEO, Howard Brody, Patient, Amyloid, Research, Incidence, Environmental Modification Convention, Cancer, PTM, Disease, Ageing, Oxidative stress, Diagnosis, Professor, Adoption, Protein, Parkinson's disease, Doctor of Philosophy, Government budget balance, Neurodegeneration, Dementia, University, Genome, Review, Population, Literature, Frontiers Media, Medical device, Medical imaging, Alzheimer's disease, Diadem

MILAN, April 28, 2022 /PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced release of a new peer-reviewed publication, Post-Translational Modifications of the p53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature, in the current issue of the journal Frontiers in Aging Neuroscience. The article reviews the extensive scientific literature that elucidates how post-translational modifications (PTMs) of the protein are associated with the development of Alzheimer's disease. Diadem is leveraging the relationship between p53 conformational variants and AD to develop blood-based prognostic and diagnostic assays for Alzheimer's disease. Its most advanced product, the AlzoSure® Predict assay, is a simple, non-invasive plasma-based biomarker test to accurately predict whether or not a patient with asymptomatic mild cognitive impairment will progress to Alzheimer's dementia up to six years before the disease fully manifests.

Key Points: 
  • The article reviews the extensive scientific literature that elucidates how post-translational modifications (PTMs) of the protein are associated with the development of Alzheimer's disease.
  • Diadem is leveraging the relationship between p53 conformational variants and AD to develop blood-based prognostic and diagnostic assays for Alzheimer's disease.
  • Oxidative stress also has a strong relationship to amyloid and tau-induced neurotoxicity, fueling feedback loops that may accelerate disease progression.
  • A key focus of the review is p53 post-translational modifications, which are seen as the most widespread and effective cellular mechanisms controlling p53 function.

Flower One Announces $10.1M USD Financing and Successful Loan Modification to Term Debt

Retrieved on: 
Monday, February 14, 2022
Tobacco, Retail, Professional Services, Finance, Environmental Modification Convention, THIS, Term loan, Cookie, CEO, Minority, Company, CFO, PIK, Cannabis, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Forward-looking statement, Heavy Hitters, Canadian Securities Exchange, Frankfurt Stock Exchange, THE, Intention, NLVO, Toshiko Meets Her Old Pals, Interest, Multilateral, FSE, F11, Automation, MI, CSE, Finance Secretary (India), COVID-19, LLC, Kiva, Bank, Management, Security (finance), Risk management, Audit, Flower

Flower One Holdings Inc. (Flower One or the Company) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced a term loan financing with an existing shareholder for aggregate proceeds of $10.1M USD (the Term Loan).

Key Points: 
  • Flower One Holdings Inc. (Flower One or the Company) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced a term loan financing with an existing shareholder for aggregate proceeds of $10.1M USD (the Term Loan).
  • In addition, the Company has made further advancements in its ongoing debt restructuring through an additional loan modification agreement (the Loan Modification Agreement) with its term lender and its affiliates.
  • The Company and certain of its subsidiaries have entered into a Loan Modification Agreement with RB Loan Portfolio II, LLC, (the Term Lender) with respect to the Companys existing $30M term debt (the Term Debt), secured by the facility at 3950 N. Bruce St., North Las Vegas, Nevada.
  • The Companys receipt of the Term Loan was facilitated by a participants purchase of the interest in the Term Debt (the Participation Interest) from the Term Lender in the amount of $10.1M.

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Retrieved on: 
Thursday, September 23, 2021
Dementia, Adoption, Neurodegeneration, Probability, Environmental Modification Convention, Research, Review, Parkinson's disease, Diagnosis, Therapy, Genome, Cancer, Patient, Pathology, Professor, Population, Protein, Disease, CEO, University, Government budget balance, Mitchell Center, Amyloid, Peripheral nervous system, Oxidative stress, Brain, Incidence, Doctor of Philosophy, Howard Brody, Neuron, Medical imaging, Medical device

Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.

Key Points: 
  • Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
  • This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
  • p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.